Company
Small Pharma, Inc.
Headquarters: London, United Kingdom
Employees: 13
CEO: Mr. Peter David Rands
Market Cap
C$22.5 Million
CAD as of July 1, 2023
US$17.0 Million
Small Pharma, Inc. Categories
United Kingdom Healthcare BiotechnologyUnited Kingdom Healthcare United Kingdom Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Small Pharma Inc., a clinical stage neuropharmaceutical company, engages in the IP-led development of novel treatments for depression and other mental health conditions. The company's lead product candidate is SPL026, a N,N-dimethyltryptamine (DMT) assisted therapy that is in Phase I/IIa randomized controlled clinical trial for the treatment of major depressive disorders. Its preclinical product candidates include SPL028 and SPL029 tryptamine analogues to assess and deliver alternative treatment profiles for the treatment of depression and other mental health disorders; and SPL801, an oral formulation of 6 -hydroxynorketamine. The company was founded in 2015 and is headquartered in London, United Kingdom.
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Small Pharma, Inc. has the following listings and related stock indices.
Stock: TSXV: DMT wb_incandescent
Stock: OTC: DMTTF wb_incandescent